An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing risk
Authors:
- 19 January 2010
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 159 (1) , 12-21
Abstract
Owing to its association with Torsades de Pointes, drug‐induced QT interval prolongation has been and remains a significant hurdle to the development of safe, effective medicines. Genetic and pharmacological evidence highlighting the pivotal role the human ether‐a‐go‐go‐related gene (hERG) channel was a critical step in understanding how to start addressing this issue. It led to the development of hERG assays with the rapid throughput needed for the short timescales required in early drug discovery. The resulting volume of hERG data has fosteredin silicomodels to help chemists design compounds with reduced hERG potency. In early drug discovery, a pragmatic approach based on exceeding a given potency value has been required to decide when a compound is likely to carry a low QT risk, to support its progression to late‐stage discovery. At this point, thein vivoefficacy and metabolism characteristics of the potential drug are generally defined, as well its safety profile, which includes usually a dog study to assess QT interval prolongation risk. The hERG andin vivoQT data, combined with the likely indication and the estimated free drug level for efficacy, are put together to assess the risk that the potential drug will prolong QT in man. Further data may be required to refine the risk assessment before making the major investment decisions for full development. The non‐clinical data are essential to inform decisions about compound progression and to optimize the design of clinical QT studies.This article is commented on by Guth and Rast, pp. 22–24 of this issue and is part of a themed section on QT safety. To view this issue visithttp://www3.interscience.wiley.com/journal/121548564/issueyear?year=2010Keywords
This publication has 45 references indexed in Scilit:
- Integrated risk assessment and predictive value to humans of non‐clinical repolarization assaysBritish Journal of Pharmacology, 2010
- Dealing with hERG liabilities early: diverse approaches to an important goal in drug developmentBritish Journal of Pharmacology, 2010
- Principles of Safety PharmacologyBritish Journal of Pharmacology, 2008
- The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeysBritish Journal of Pharmacology, 2008
- Strategies to reduce the risk of drug‐induced QT interval prolongation: a pharmaceutical company perspectiveBritish Journal of Pharmacology, 2008
- In vitro models of proarrhythmiaBritish Journal of Pharmacology, 2008
- Predicting drug‐induced changes in QT interval and arrhythmias: QT‐shortening drugs point to gaps in the ICHS7B GuidelinesBritish Journal of Pharmacology, 2008
- Drugs and trafficking of ion channels: a new pro‐arrhythmic threat on the horizon?British Journal of Pharmacology, 2008
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizoleFEBS Letters, 1996